Oral oncology最新文献

{"title":"Commentary on “Transoral robotic surgery in oral tongue cancer patients with trismus: A retrospective evaluation of feasibility and surgical outcomes,”","authors":"Jenefar Sudarson","doi":"10.1016/j.oraloncology.2025.107773","DOIUrl":"10.1016/j.oraloncology.2025.107773","url":null,"abstract":"<div><div>The recent paper by Pan et al. (2025), entitled “<em>Transoral robotic surgery in oral tongue cancer patients with trismus: a retrospective evaluation of feasibility and surgical outcomes</em>,” marks an important milestone in head and neck surgery. This commentary highlights that transoral robotic surgery (TORS) is safe and effective for oral tongue cancer patients, trismus. The high negative margin rate (98.5%) and absence of complications or conversions to open surgery provide strong evidence for the feasibility and oncological efficacy of TORS. The study suggests that improved mouth opening post-operatively, through release of fibrotic tissue intra-operatively, offers a two-fold benefit of oncologic surgical resection and trismus relief. These outcomes are consistent with the gradual shift in surgical paradigms emphasizing function preservation and improving access through precision. Although retrospective and single center, multicenter and prospective trials assessing functional recovery, trismus recurrence and quality of life should be conducted. The study arrives at an optimal time, redefining surgical candidacy and enhancing robotic surgery application for complex malignancies in the oral cavity.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107773"},"PeriodicalIF":3.9,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145468319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study","authors":"Paulien Van Loocke ,&nbsp;Benoit Beuselinck ,&nbsp;Jeroen Meulemans ,&nbsp;Sandra Nuyts ,&nbsp;Robin Willaert ,&nbsp;Davide Di Santo ,&nbsp;Esther Hauben ,&nbsp;Robert Hermans ,&nbsp;Abhishek D. Garg ,&nbsp;Vincent Vander Poorten ,&nbsp;Oliver Bechter ,&nbsp;Paul M. Clement","doi":"10.1016/j.oraloncology.2025.107772","DOIUrl":"10.1016/j.oraloncology.2025.107772","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107772"},"PeriodicalIF":3.9,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145468318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative pembrolizumab and the changing paradigm of adjuvant therapy in head and neck squamous cell carcinoma: the case of T1-2, pN1","authors":"Giancarlo Tirelli,&nbsp;Paolo Boscolo-Rizzo","doi":"10.1016/j.oraloncology.2025.107770","DOIUrl":"10.1016/j.oraloncology.2025.107770","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107770"},"PeriodicalIF":3.9,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145459374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of head and neck cancer around the world: an international survey by the world ear, nose, and throat federation","authors":"Victorine Maso ,&nbsp;Jerome R Lechien ,&nbsp;Isabelle Gengler ,&nbsp;Carlos Chiesa-Estomba ,&nbsp;Johannes J. Fagan ,&nbsp;Sheng-Po Hao ,&nbsp;Luiz P. Kowalski ,&nbsp;Bernard Lyons ,&nbsp;Emmanuel Babin ,&nbsp;Mohamad Yunus Mohd Razif ,&nbsp;Hani Z. Marzouki ,&nbsp;Angel Ramos Macias ,&nbsp;Hector E. Ruiz ,&nbsp;Antonino Maniaci ,&nbsp;Bernard Fraysse ,&nbsp;Matthew White ,&nbsp;Justin Michel ,&nbsp;Nicolas Fakhry","doi":"10.1016/j.oraloncology.2025.107766","DOIUrl":"10.1016/j.oraloncology.2025.107766","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate worldwide medical practices of otolaryngology centers in managing patients with Head And Neck Cancer (HNC)</div></div><div><h3>Materials and Methods</h3><div>We performed an online survey sent to otorhinolaryngologists worldwide via the IFOS between February and March 2024. The following aspects were evaluated: personal characteristics, diagnostics modalities, treatments, global management, cultural specificities and clinical cases. We compared results between centers in different geographical areas: Europe, North America, South and Central America, Asia, Africa Sub-Saharan, Oceania, and Middle East &amp; North Africa (MENA).</div></div><div><h3>Results</h3><div>A total of 566 otorhinolaryngologists from 457 centers in 101 countries responded. International guideline adherence was lower in North America (45.5 %) than globally (74.5 %; p = 0.005). HPV/p16 testing was less common in Africa (28.9 %) and MENA (60.8 %) versus other regions (92.8 %; p &lt; 0.001). PD-L1 testing was frequent in Europe (84.6 %) but rare in Africa (5.3 %; p &lt; 0.001). Multidisciplinary Tumor Boards were systematic in Europe (88.9 %) and Oceania (87.5 %) but used selectively elsewhere. Intensity-modulated radiation therapy use was lower in Africa (28.9 %) and MENA (64.6 %; p &lt; 0.001). A total of 95.7 % of centers had access to chemotherapy, with no differences between regions (p = 0.236). African centers cited cost as a major barrier (79.5 % vs. 33.8 %; p &lt; 0.001). MRI and PET/CT access was significantly lower in Africa (51.2 % and 5 %), Central/South America (79.5 % and 47.7 %), and MENA (80.9 % and 43.8 %) than other regions (89.5 % and 73.2 %; p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>The management of HNC exhibits significant variability worldwide. International guidelines should consider the economic, cultural, and geographic specificities of each continent to ensure context-sensitive care.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107766"},"PeriodicalIF":3.9,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response-adapted surgery after neoadjuvant immunochemotherapy in oral squamous cell carcinoma","authors":"Qigen Fang ,&nbsp;Junhui Yuan ,&nbsp;Xu Zhang ,&nbsp;Tao Huang ,&nbsp;Lanwei Guo","doi":"10.1016/j.oraloncology.2025.107769","DOIUrl":"10.1016/j.oraloncology.2025.107769","url":null,"abstract":"<div><h3>Objective</h3><div>The standard treatment for locally advanced oral squamous cell carcinoma (OSCC) involves radical surgery followed by adjuvant therapy, often resulting in significant functional impairment. Neoadjuvant immunochemotherapy (NICT) has emerged as a promising strategy to facilitate surgical de-escalation while preserving oncologic outcomes. This study evaluates the feasibility of response-adapted surgery (RAS) following NICT in OSCC.</div></div><div><h3>Methods</h3><div>In this retrospective analysis, 152 patients with previously untreated OSCC received NICT followed by either RAS (n = 66) or traditional surgery (TS, n = 86). RAS was tailored to post-NICT tumor regression, while TS adhered to pretreatment tumor extent. Primary endpoints were 3-year event-free survival (EFS) and overall survival (OS). Secondary endpoints included quality of life (QoL, assessed via EORTC QLQ-HN35) and perioperative complications.</div></div><div><h3>Results</h3><div>The RAS and TS cohorts exhibited comparable 3-year EFS (78.8 % vs. 79.1 %, p = 0.944) and OS (90.9 % vs. 91.9 %, p = 0.826). RAS significantly reduced the need for mandibulectomy (16.7 % vs. 41.9 %, p = 0.009) and free flap reconstruction (15.2 % vs. 48.8 %, p = 0.018), with fewer major complications (4.5 % vs. 11.6 %, p = 0.048). QoL metrics favored RAS, particularly in swallowing (15 ± 3.8 vs. 28 ± 5.5, p &lt; 0.001) and speech (14 ± 3.9 vs. 25 ± 5.2, p &lt; 0.001) at 12 months. Major pathologic response and PD-L1 CPS &gt; 20 were associated with improved survival.</div></div><div><h3>Conclusions</h3><div>RAS after NICT achieves oncologic outcomes equivalent to TS while significantly reducing treatment-related morbidity and improving functional recovery. These findings support RAS as a viable de-escalation strategy for OSCC, aligning with the goals of precision oncology. Prospective trials are needed to validate long-term efficacy and refine patient selection criteria.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107769"},"PeriodicalIF":3.9,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitivity of post-treatment surveillance in detecting recurrence and metastasis in surgically treated HPV-positive oropharyngeal squamous cell carcinoma patients","authors":"Agnes Q Zhu ,&nbsp;Claire E Cassianni ,&nbsp;Travis Haller ,&nbsp;Thomas J. O’Byrne ,&nbsp;Pablo Ochoa ,&nbsp;Tissiana Vallecillo ,&nbsp;Andrew Pumford ,&nbsp;Felicia Olawuni ,&nbsp;Eric J Moore ,&nbsp;Daniel L Price ,&nbsp;Kendall K Tasche ,&nbsp;Linda X Yin ,&nbsp;Daniel J Ma ,&nbsp;Scott C Lester ,&nbsp;Mauricio Gamez ,&nbsp;Michelle A Neben Wittich ,&nbsp;Katharine A Price ,&nbsp;Kathryn M Van Abel ,&nbsp;David M Routman","doi":"10.1016/j.oraloncology.2025.107767","DOIUrl":"10.1016/j.oraloncology.2025.107767","url":null,"abstract":"<div><h3>Introduction</h3><div>There is a lack of data regarding the appropriate surveillance of HPV(+)OPSCC. Our study aims to determine the sensitivity of patient symptoms, physical exam findings, and imaging in identifying recurrence and disease progression.</div></div><div><h3>Methods</h3><div>Mayo Clinic IRB (22–000684) approval was obtained, and the departmental REDCap database was queried to identify all HPV(+)OPSCC patients from 01/01/2006 to 12/31/2021 at our tertiary care center. Surgically treated patients with pathologic specimens positive for HPV (confirmed with in-situ hybridization (ISH) and/or p16 immuno-histochemistry) without evidence of distant metastatic disease at diagnosis were included.<!--> <!-->Sensitivity, specificity, PPV, and NPV of patient symptoms, physical exam findings, and imaging for disease progression were assessed both overall and at each time point.</div></div><div><h3>Results</h3><div>142/1142 patients experienced disease progression. 70% of patients with disease progression were detected within the first two years of surveillance. 79 patients with disease progression were detected via routine surveillance imaging, 34 via patient-reported symptoms, and 5 via physical exam.</div><div>Routine surveillance imaging was the most sensitive method of detection for locoregional recurrence (sensitivity 92.3%, PPV 6.5%, NPV 42.9%) and distant metastasis (sensitivity 100%, PPV 6.7%, NPV 100.0%). Patient symptoms in aggregate had a 73.1% sensitivity for detecting locoregional recurrence (PPV 8.7%, NPV 95.4%); however no individual symptom had a sensitivity over 30%. Physical exam findings were the least sensitive method of detection.</div></div><div><h3>Conclusion</h3><div>Our findings demonstrate that the majority of recurrences are detected within the first two years of surveillance. Routine surveillance imaging is the most sensitive modality for detecting disease progression as compared to patient symptoms or physical exam findings. Additional studies integrating newer technologies, such as ctHPVDNA. into surveillance are needed.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107767"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145420249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable complete response to tislelizumab plus cetuximab in a 94-year-old patient with advanced lower lip squamous cell carcinoma: A case report and literature review","authors":"Shi-Qiong Zhou ,&nbsp;Sen Zhang ,&nbsp;Qing-Hua Ke","doi":"10.1016/j.oraloncology.2025.107765","DOIUrl":"10.1016/j.oraloncology.2025.107765","url":null,"abstract":"<div><h3>Background</h3><div>Lip squamous cell carcinoma (SCC) is a rare subtype of head and neck squamous cell carcinoma (HNSCC), accounting for approximately 1 % of all oral malignancies. Unlike other oral SCCs (e.g., tongue or buccal SCC), lip SCC has distinct epidemiological features: it shows a stronger association with chronic sun exposure (especially ultraviolet radiation) and a lower correlation with smoking/alcohol consumption. It is more common in elderly males, and advanced cases with lymph node metastasis are associated with poor prognosis. The treatment of advanced lip SCC in elderly patients is uniquely challenging due to its anatomical location (functional and aesthetic importance), which makes aggressive therapies like surgery more likely to cause functional impairment (e.g., difficulty in mouth opening or speech) and poor tolerance to such therapies due to comorbidities [1–3].</div></div><div><h3>Case summary</h3><div>A 94-year-old female patient presented with a progressively enlarging mass on the right lower lip, which was diagnosed as poorly differentiated squamous cell carcinoma with neck lymph node metastasis (cT4N2M0). Due to her advanced age and late-stage disease, she was not eligible for surgery, radiotherapy, or chemotherapy. She received combination therapy with tislelizumab (200 mg intravenously every 3 weeks) and cetuximab (400 mg/m² intravenously every 2 weeks) starting from November 27, 2024. Significant improvement of the lip mass was observed after treatment, and complete response was achieved on January 8, 2025, after two cycles of treatment. Consolidation therapy was continued for six months, with no recurrence or metastasis during follow-up. As of July 31, 2025 (6 months after initial treatment), the patient remains in complete response with regular follow-up. Immunohistochemical analysis showed PD-L1 positivity with a combined positive score (CPS) of 80, which may predict a favorable response to immunotherapy.</div></div><div><h3>Conclusion</h3><div>This case demonstrates that the combination of tislelizumab and cetuximab can achieve remarkable efficacy in elderly patients with advanced lip SCC, even without surgery, radiotherapy, or chemotherapy. PD-L1 high expression (CPS = 80) may serve as a valuable predictive biomarker for immunotherapy response in such cases. Six months follow-up confirms the durability of the response, supporting the potential of this regimen in extreme elderly populations.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107765"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145420250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-surgery billing in head and neck free-flap reconstruction: trends and reimbursement patterns under medicare","authors":"Daniel Gilmore ,&nbsp;Nolan B. Seim ,&nbsp;Lauren E. Miller","doi":"10.1016/j.oraloncology.2025.107763","DOIUrl":"10.1016/j.oraloncology.2025.107763","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107763"},"PeriodicalIF":3.9,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145409636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: “Patterns of care in de‑novo oligo‑metastatic and oligo‑recurrent head and neck cancers: A HNCIG survey” (Oral oncology)","authors":"Nengjun Xiang ,&nbsp;Wentao Li","doi":"10.1016/j.oraloncology.2025.107749","DOIUrl":"10.1016/j.oraloncology.2025.107749","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107749"},"PeriodicalIF":3.9,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The low evidence to treat elderly patients with head and neck cancer","authors":"Beatriz Bertin ,&nbsp;Luiz Paulo Kowalski ,&nbsp;Leandro Luongo Matos","doi":"10.1016/j.oraloncology.2025.107764","DOIUrl":"10.1016/j.oraloncology.2025.107764","url":null,"abstract":"<div><div>Treatment of head and neck cancer in older patients is particularly complex, as they are more prone to side effects and treatment-related toxicity due to age-related physiological changes. Nevertheless, they should still receive care based on the best available standards and protocols, since alternative approaches may increase the risk of treatment failure and mortality. The core issue lies in the lack of evidence-based protocols tailored to the specific needs of older patients, as most clinical trials seam to focus on younger populations. The objective of this study was to determine the rate of patients over 65 years of age included in clinical trials of treatments for head and neck cancer. In this context, the study aims to shed light on the proportion of clinical evidence that can be safely extrapolated to the treatment of older patients with head and neck cancer. To achieve this, we analyzed the age distribution of patients enrolled in clinical trials cited by the National Comprehensive Cancer Network (NCCN) in the NCCN Guidelines Version 2.2025: Head and Neck Cancers. Less than one-fourth of patients enrolled in the NCCN-referenced clinical trials were over 65 years of age, reinforcing concerns about the applicability of current protocols to this population. To address this gap, the most effective strategy is to promote the generation and dissemination of evidence-based data that actively includes older adults worldwide.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107764"},"PeriodicalIF":3.9,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}